Dr. Ori Ben-Yehuda, the Executive Director of the CRF Clinical Trials Center, was interviewed as part of a special series by MedPage Today about PCSK9 drugs. He spoke about the potential implications (risks and benefits) of lowering LDL levels below recommended levels for patients.